Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Portal vein invasion (PVI) is a poor prognostic factor in patients with hepatocellular carcinoma (HCC). We intended to compare the effects of surgical resection and transarterial chemoembolization (TACE) with additional radiation therapy (RT) in HCC patients with PVI. Methods: The subjects comprised 43 patients who underwent surgical resection for HCC with PVI without previous treatment and another 43 patients who received TACE followed by RT (TACE+RT) as initial treatment who were matched for Child-Pugh class, tumor size, and extent of PVI. Disease progression and death after the treatment were examined, and progression-free survival (PFS) and overall survival (OS) were compared between groups. Predisposing factors affecting OS were analyzed using univariate and multivariate analyses in HCC patients with PVI. Results: The subjects (Age [51, 24-74; median, range], Sex [81/13; male/female], Etiology [78/1/15; hepatitis B virus {HBV}/ hepatitis C virus {HCV}/non-HBV and non-HCV]) were followed for a median of 17 (2-68) months. There were no differences in clinical or tumor characteristics between the resection and TACE+RT groups. The cumulative PFS was not significantly different between groups. The median PFS was 5.6 and 4.0 months in the resection and TACE+RT groups, respectively. However, the cumulative OS was significantly longer in patients treated with resection than in those treated with TACE+RT (P=0.04). The median OS was 26.9 and 14.2 months in the resection and TACE+RT groups, respectively. Univariate and multivariate analyses revealed that surgical resection was an independent predictive factor for better survival outcome. Conclusions: Surgical resection might be an effective treatment in HCC patients with PVI.
Abstract
Background/Aims: Portal vein invasion (PVI) is a poor prognostic factor in patients with hepatocellular carcinoma (HCC). We intended to compare the effects of surgical resection and transarterial chemoembolization (TACE) with additional radiation therapy (RT) in HCC patients with PVI. Methods: The subjects comprised 43 patients who underwent surgical resection for HCC with PVI without previous treatment and another 43 patients who received TACE followed by RT (TACE+RT) as initial treatment who were matched for Child-Pugh class, tumor size, and extent of PVI. Disease progression and death after the treatment were examined, and progression-free survival (PFS) and overall survival (OS) were compared between groups. Predisposing factors affecting OS were analyzed using univariate and multivariate analyses in HCC patients with PVI. Results: The subjects (Age [51, 24-74; median, range], Sex [81/13; male/female], Etiology [78/1/15; hepatitis B virus {HBV}/ hepatitis C virus {HCV}/non-HBV and non-HCV]) were followed for a median of 17 (2-68) months. There were no differences in clinical or tumor characteristics between the resection and TACE+RT groups. The cumulative PFS was not significantly different between groups. The median PFS was 5.6 and 4.0 months in the resection and TACE+RT groups, respectively. However, the cumulative OS was significantly longer in patients treated with resection than in those treated with TACE+RT (P=0.04). The median OS was 26.9 and 14.2 months in the resection and TACE+RT groups, respectively. Univariate and multivariate analyses revealed that surgical resection was an independent predictive factor for better survival outcome. Conclusions: Surgical resection might be an effective treatment in HCC patients with PVI.
참고문헌 (24)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)[DOI]
- Poon RT, "Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma", Cancer, 89, pp.500~507 (2000)[DOI]
- Minagawa M, "Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus", World J Gastroenterol, 12, pp.7561~7567 (2006)[DOI]
- Shah SA, "Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes", Surgery, 141, pp.330~339 (2007)[DOI]
- Liu PH, "Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis", Ann Surg Oncol, 21, pp.1825~1833 (2014)[DOI]
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)[DOI]
- de Lope CR, "Management of HCC", J Hepatol, 56(Suppl 1), pp.S75~S87 (2012)
- Kim KM, "Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion", J Gastroenterol Hepatol, 24, pp.806~814 (2009)[DOI]
- Luo J, "Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study", Ann Surg Oncol, 18, pp.413~420 (2011)[DOI]
- Omata M, "Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma", Hepatol Int, 4, pp.439~474 (2010)[DOI]
- Tazawa J, "Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement", J Gastroenterol Hepatol, 16, pp.660~665 (2001)[DOI]
- Zeng ZC, "A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and", or inferior vena cava tumor thrombus, 2005, pp.61, 432~443
- Shi J, "Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus", Ann Surg Oncol, 17, pp.2073~2080 (2010)[DOI]
- Kokudo T, "Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion", J Hepatol, 65, pp.938~943 (2016)[DOI]
- Zhang YF, "Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score analysis", Oncotarget, 7, pp.38845~38856 (2016)
- Mayer KH, "Comprehensive clinical care for men who have sex with men: an integrated approach", Lancet, 380, pp.378~387 (2012)[DOI]
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)[DOI]
- Cheng AL, "Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial", Eur J Cancer, 48, pp.1452~1465 (2012)[DOI]
- Kumada K, "Hepatic resection for advanced hepatocellular carcinoma with removal of portal vein tumor thrombi", Surgery, 108, pp.821~827 (1990)
- Chen XP, "Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma", Ann Surg Oncol, 13, pp.940~946 (2006)[DOI]
- Kojima H, "Hepatic resection for hepatocellular carcinoma with tumor thrombus in the major portal vein", Dig Surg, 32, pp.413~420 (2015)[DOI]
- Minagawa M, "Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus", Ann Surg, 233, pp.379~384 (2001)[DOI]
- Koo JE, "Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus", Int J Radiat Oncol Biol Phys, 78, pp.180~187 (2010)[DOI]
- Peng ZW, "Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus", Cancer, 118, pp.4725~4736 (2012)[DOI]